Healthcare stocks rally as sector rotation lifts Cardinal Health, J&J and Eli Lilly

Traders Union
All News
Financial News
Healthcare stocks rally lifts sector

Highlights

Healthcare leads S&P 500 sectors this week, up over 7%, as investors rotate out of AI stocks and into defensive names like Cardinal Health, Johnson & Johnson, and Eli Lilly.
Honeywell's breakup occurs next week, with investors receiving one Honeywell Aerospace share (HONA) for every two Honeywell shares, while Honeywell Technologies executes a 1-for-2 reverse stock split.
RBC Capital initiated coverage on Honeywell Aerospace with a buy-equivalent rating and a $300 target, citing attractive valuation versus RTX and stronger long-term growth prospects.

Healthcare surge reshapes weekly market leadership

As reported by CNBC, healthcare is emerging as the top-performing S&P 500 sector this week, rising more than 7% as investors shift out of high-flying AI stocks and into more defensive names.

The broader market remains uneven on Friday, with the S&P 500 moving in and out of positive territory and heading for a weekly decline of almost 2%. Oil prices are lower again, leaving U.S. benchmark WTI crude on track to finish the week below $70 a barrel, while the 10-year Treasury yield stays under 4.4%.

Within healthcare, Cardinal Health, Johnson & Johnson and Eli Lilly are all outperforming the market and are on track for record closes. The move appears driven more by market positioning than by any fundamental change in the companies' outlooks, with investors rotating into the sector as enthusiasm around AI cools.

Portfolio focus turns to Honeywell and Nike

Honeywell's long-awaited breakup is scheduled for next week, creating two standalone companies. Shareholders are set to receive one share of Honeywell Aerospace, ticker HONA, for every two Honeywell shares they own, while the remaining business, Honeywell Technologies, is set to complete a 1-for-2 reverse stock split.

Analysts at RBC Capital initiated coverage of Honeywell Aerospace on Friday with a buy-equivalent rating and a $300 price target. The aerospace business is seen as better positioned for long-term growth and as relatively inexpensive compared with RTX on an enterprise value-to-EBITDA basis, while Honeywell Technologies is viewed as needing to prove that its portfolio reshaping can deliver stronger growth and earnings quality.

Investors are also watching Nike's earnings report due Tuesday after the closing bell, in what is described as a make-or-break quarter for the stock's place in the portfolio. On the macroeconomic side, the June nonfarm payrolls report is due Thursday instead of the usual Friday because U.S. markets are closed for the Independence Day holiday.

Our earlier coverage of Eli Lilly’s Jaypirca regulatory milestone highlighted how the EMA’s positive recommendation could expand the drug’s addressable market in Europe and support the stock’s momentum. We also noted that Lilly’s acquisitions and international launches were reinforcing its pipeline-driven growth story, while technical indicators pointed to a bullish setup with a potential consolidation range before another breakout attempt.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.